cas 3034-22-8|| where to buy 5-bromo-1,3-thiazol-2-amine

Название продукции:5-bromo-1,3-thiazol-2-amine

IUPAC Name:5-bromo-1,3-thiazol-2-amine

Упаковочная единица	Доступно для заказа	Цена ($)
CM104786-25g	in stock	ȃƥ
CM104786-100g	in stock	ľǙǙ
CM104786-500g	in stock	ŗůƿ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3034-22-8 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:3034-22-8; Молекулярная формула:C3H3BrN2S; Точка плавления:-; Smiles-код:NC1=NC=C(Br)S1; Плотность:

: Номер в каталоге:CM104786; Молекулярная масса:179.04; Точка кипения:; Номер Mdl:MFCD00016893; Хранение:

: Thiazoles; Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.

: Cadisegliatin; vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.